Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
Blaise
D
D
BMT Unit, Institut Paoli Calmettes, Marseille, France.
Stoppa
A M
AM
Olive
D
D
Brandely
M
M
Tiberghien
P
P
Attal
M
M
Attal
J
J
Reiffers
J
J
Demeocq
F
F
Pico
J L
JL
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007938:Leukemia / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous
D007155:Immunologic Factors; D007376:Interleukin-2; D011994:Recombinant Proteins